B+
Bull case
20%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
CNTX
Context TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$0.38
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.15
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-09
Recent news sentiment (30D)
-0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+76.6
Score
AI commentary
The stock anchor was $0.3763 on 2026-09-08. Recent coverage highlighted a severe post-ovarian-cancer-data selloff, while analyst revisions, options data, short interest, employee-review data, and social coverage are unavailable [#SERP-1]. Company-reported milestones and runway provide support, but forward visibility remains limited and binary; this is a cautious monitoring view rather than a high-conviction bullish thesis.
RankAlpha Sentiment Codex - 2026-09-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30eventCT-202 first patient dosingHigh impact
Management expected the first patient dose in the Phase 1 CT-202 trial during Q3 2026, covering urothelial, colorectal, and triple-negative breast cancers [#PR-EARNINGS-2026-08-05].
2026-12-31catalystPipeline concentration increases binary execution riskHigh impact
Context is discontinuing CT-95 and concentrating development on CTIM-76 and CT-202, increasing dependence on a small number of clinical programs [#PR-EARNINGS-2026-08-05].
2027-06-30eventCTIM-76 Q3W development updateHigh impact
The company plans to evaluate every-three-week dosing in less heavily pretreated platinum-resistant ovarian-cancer patients in the second half of 2026, with initial Q3W data expected in Q2 2027 [#PR-EARNINGS-2026-08-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-09 • Updated nightlySource: Internal modelMethodology